Search Results - Torben Plesner

Refine Results
  1. 1
    Daratumumab for the Treatment of Multiple Myeloma

    Daratumumab for the Treatment of Multiple Myeloma by Torben Plesner, Jakub Krejcik

    Published 2018
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR

    Structure, Function and Expression on Blood and Bone Marrow Cells of the Urokinase‐Type Plasminogen Activator Receptor, uPAR by Torben Plesner, Niels Behrendt, Michael Ploug

    Published 1997
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Myeloma cell‐induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast‐myeloma hybrid cells

    Myeloma cell‐induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast‐myeloma hybrid cells by Thomas Levin Andersen, Kent Søe, Teis Esben Søndergaard, Torben Plesner, Jean‐Marie Delaissé

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation

    Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation by Patrice Boissy, Thomas Levin Andersen, Basem M. Abdallah, Moustapha Kassem, Torben Plesner, Jean‐Marie Delaissé

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria

    The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria by Michael Ploug, Torben Plesner, Ebbe Rønne, Vincent Ellis, G Hoyer-Hansen, NE Hansen, Keld Danø

    Published 1992
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

    Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells by Therese Standal, Carina Seidel, Øyvind Hjertner, Torben Plesner, Ralph D. Sanderson, Anders Waage, Magne Börset, Anders Sundan

    Published 2002
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils

    The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neut... by Torben Plesner, Michael Ploug, Vincent Ellis, Ebbe Rønne, Gunilla Høyer‐Hansen, M Wittrup, TL Pedersen, T Tscherning, Keld Danø, NE Hansen

    Published 1994
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone

    A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone by Thomas Levin Andersen, Teis Esben Søndergaard, Katarzyna Skórzyńska-Dziduszko, Frederik Dagnæs‐Hansen, Trine Lindhardt Plesner, Ellen‐Margrethe Hauge, Torben Plesner, Jean‐Marie Delaissé

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy <i>versus</i> glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia

    A phase <scp>III</scp> randomized trial comparing glucocorticoid monotherapy <i>versus</i> glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia by Henrik Birgens, Henrik Frederiksen, Hans Carl Hasselbalch, Inge Helleberg Rasmussen, Ove Juul Nielsen, Lars Kjeldsen, Herdis Larsen, Torben Mourits‐Andersen, Torben Plesner, Dorthe Rønnov‐Jessen, Hanne Vestergaard, Tobias Wirenfeldt Klausen, Claudia Schöllkopf

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma

    Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma by Niels W.C.J. van de Donk, Philippe Moreau, Torben Plesner, Antonio Palumbo, Francesca Gay, Jacob P. Laubach, Fabio Malavasi, Hervé Avet‐Loiseau, María‐Victoria Mateos, Pieter Sonneveld, Henk M. Lokhorst, Paul G. Richardson

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

    Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma by Jakub Krejcik, Tineke Casneuf, Inger S. Nijhof, Bie Verbist, Jaime Bald, Torben Plesner, Khaja Syed, Kevin Liu, Niels W.C.J. van de Donk, Brendan M. Weiss, Tahamtan Ahmadi, Henk M. Lokhorst, Tuna Mutis, A. Kate Sasser

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    The Danish National Multiple Myeloma Registry

    The Danish National Multiple Myeloma Registry by Peter Gimsing, Morten Orebo Holmström, Tobias Wirenfelt Klausen, Niels Frost Andersen, Henrik Gregersen, Robert Schou Pedersen, Torben Plesner, Per Trøllund Pedersen, Mikael Frederiksen, Ulf Christian Frølund, Carsten Helleberg, Annette Juul Vangsted, Peter de Nully Brown, Niels Abildgaard

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

    Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma by Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu, Imran Khan, Tahamtan Ahmadi, Xiaoyu Yan, Sagar Lonial, Torben Plesner, Henk M. Lokhorst, Niels W.C.J. van de Donk, Pamela L. Clemens, A. Kate Sasser

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura

    Rituximab chimeric anti‐CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura by Peter Brændstrup, Ole Weis Bjerrum, Ove Juul Nielsen, Bjarne Anker Jensen, Nielsaage Tøffner Clausen, Per Boye Hansen, Ivan Andersen, Kai Gjerløff Schmidt, Torben M. Andersen, Niels Anker Peterslund, Henrik Birgens, Torben Plesner, Bjarne Bach Pedersen, Hans Carl Hasselbalch

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)

    Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14) by Nizar J. Bahlis, Rachid Baz, Simon J. Harrison, Hang Quach, Shir‐Jing Ho, Annette Juul Vangsted, Torben Plesner, Philippe Moreau, Simon Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A. Ross, Orlando F. Bueno, Jonathan L. Kaufman

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference

    Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference by Christopher R. McCudden, Amy Axel, Dominique Slaets, Thomas Dejoie, Pamela L. Clemens, Sandy Frans, Jaime Bald, Torben Plesner, Joannes F.M. Jacobs, Niels W.C.J. van de Donk, Philippe Moreau, Jordan M. Schecter, Tahamtan Ahmadi, A. Kate Sasser

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

    Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia by Sif Gudbrandsdottir, Henrik Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits‐Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, Stanislaw Pulczynski, Inge Helleberg Rasmussen, Dorthe Rønnov‐Jessen, Hans Carl Hasselbalch

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

    Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma by Saad Z. Usmani, Brendan M. Weiss, Torben Plesner, Nizar J. Bahlis, Andrew Belch, Sagar Lonial, Henk M. Lokhorst, Peter M. Voorhees, Paul G. Richardson, Ajai Chari, A. Kate Sasser, Amy Axel, Huaibao Feng, Clarissa Uhlar, Jianping Wang, Imran Khan, Tahamtan Ahmadi, Hareth Nahi

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

    Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma by Saad Z. Usmani, Hareth Nahi, María‐Victoria Mateos, Niels W.C.J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesús F. San Miguel

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma

    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma by Torben Plesner, Simon J. Harrison, Hang Quach, Cindy Lee, Adam Bryant, Annette Juul Vangsted, Jane Estell, Michel Delforge, Fritz Offner, Patrick J. Twomey, Voleak Choeurng, Junyi Li, Robert L. Hendricks, Shannon M. Ruppert, Teiko Sumiyoshi, Karen K. Miller, Eunpi Cho, Fredrik Schjesvold

    Published 2023
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: